NVO Jan 2026 62.500 call
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiat
- Zacks
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.
- Reuters
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
A U.S. Senate health panel vote that was scheduled for its June 18 meeting, to decide whether to subpoena Novo to answer questions about U.S. prices for the blockbuster drugs, is no longer necessary and will be canceled, Senator Bernie Sanders, who chairs the committee, said. The subpoena would have required Novo President Doug Langa to testify at a July 10 hearing. Jorgensen will testify before the committee, and the hearing will be held in early September.
